Merck Call Options Surge on Positive Cancer Vaccine Trial Results

Key Facts

In a move reflecting significant optimism within the biotechnology sector, Merck & Co. experienced an exceptional surge in bullish trading activity. According to reports, call option volume jumped 188% above the typical daily average, driven by robust clinical data. This spike follows the announcement of Phase 3 trial results from the Merck-Moderna alliance, which demonstrated significant improvement in recurrence-free survival rates for melanoma patients.

Markets reacted positively to these results, which proved the superiority of the new vaccine combination compared to Keytruda monotherapy, boosting investor confidence despite the stock trading at elevated levels. Per market data, MRK shares closed at $135.18 on August 18, 2026, while related instruments in European markets, 0QAH.L and 6MK.DE, closed at 150.09 and 128.38 respectively as of August 19, 2026.

Traders are currently monitoring the stock's ability to maintain this upward momentum, especially as it trades near 52-week highs and above average analyst price targets. Based on price levels from August 18, 2026, the $137.98 level (MRK's daily high) represents a near-term resistance point for investors, given the absence of direct macroeconomic catalysts for the pharmaceutical sector in the upcoming economic calendar.